Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Connective tissue growth factor (CTGF), also known as CCN2, plays a significant role in tissue repair, fibrosis, and the wound healing process. Scientific studies demonstrate that CTGF is actively involved in the regulation of extracellular matrix production, cell adhesion, and proliferation during scar formation. Elevated expression of CTGF has been consistently found in fibrotic tissues and pathological scars, such as keloids and hypertrophic scars. Experimental models, both in vitro and in vivo, have shown that targeting CTGF—using antibodies, siRNA, or pharmacological inhibitors—can reduce excessive scar tissue formation and fibrosis. Conversely, therapeutic administration of CTGF itself is not commonly used to support or treat scars; rather, the focus is on inhibiting its activity to prevent or mitigate abnormal scarring. Clinical trials have investigated anti-CTGF therapies (e.g., pamrevlumab) for fibrotic diseases, and early-stage studies suggest potential benefits in modulating scar formation. Thus, while there is substantial evidence supporting the role of CTGF in scar biology, current therapeutic strategies are primarily aimed at suppressing, rather than supplementing, CTGF activity. The evidence base for directly using CTGF to support or treat scars is limited, but the scientific understanding of its role in scar tissue dynamics is strong, warranting a moderate rating.

More about Connective tissue growth factor
More about Scars / Scar Tissue

Other ingredients used for Scars / Scar Tissue

Other health conditions supported by Connective tissue growth factor

Products containing Connective tissue growth factor